Lorrain Daniel S. 4

What Happened Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics (CTNM), sold a total of 4,170 shares in open‑market transactions on February 3, 2026. The Form 4 reports two aggregated sales: 3,000 shares at a weighted average price of $14.82 for $44,469, and 1,170 shares at a weighted average price of $15.25 for $17,837 — total proceeds ≈ $62,306. These were sales (not purchases), and were executed under a pre‑planned trading arrangement.

Key Details

• Transaction date: February 3, 2026 (reported on Form 4 filed February 5, 2026).
• Reported prices/amounts: 3,000 shares @ $14.82 = $44,469; 1,170 shares @ $15.25 = $17,837; total ≈ $62,306.
• Price ranges: the 3,000‑share block was sold across prices from $14.12–$15.08 (weighted avg $14.82); the 1,170‑share block across $15.12–$15.45 (weighted avg $15.25).
• Footnotes: trades were effected pursuant to a 10b5‑1 trading plan adopted Sept 23, 2025. The filer offers to provide per‑price breakdowns on request.
• Shares owned after transaction: not provided in the supplied data.
• Timeliness: Form 4 was filed two days after the trades (Feb 5 for Feb 3), consistent with routine filing timing.

Context

• These sales were made under a 10b5‑1 plan, meaning they were pre‑arranged and may not reflect the insider’s current view of the company. Sales by insiders are common for liquidity or diversification and are typically less informative than purchases.
• No options were exercised and no awards or gifts were reported in this filing; both transactions are straightforward open‑market sales.